{
    "id": 26754,
    "fullName": "CD27 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "CD27 positive indicates the presence of the CD27 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 939,
        "geneSymbol": "CD27",
        "terms": [
            "CD27",
            "S152",
            "S152. LPFS2",
            "T14",
            "TNFRSF7",
            "Tp55"
        ]
    },
    "variant": "positive",
    "createDate": "07/18/2017",
    "updateDate": "10/08/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11460,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Varlilumab resulted in antitumor activity in patients with renal cell carcinoma including one patient with 78% lesion shrinkage, another patient with 18% lesion shrinkage, and four patients with stable disease lasting greater than 5 months (PMID: 28463630).",
            "molecularProfile": {
                "id": 28056,
                "profileName": "CD27 positive"
            },
            "therapy": {
                "id": 2525,
                "therapyName": "Varlilumab",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9482,
                    "pubMedId": 28463630,
                    "title": "Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28463630"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11462,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Varlilumab resulted in stable disease for 11.5 months in a patient with uveal melanoma (PMID: 28463630).",
            "molecularProfile": {
                "id": 28056,
                "profileName": "CD27 positive"
            },
            "therapy": {
                "id": 2525,
                "therapyName": "Varlilumab",
                "synonyms": null
            },
            "indication": {
                "id": 6039,
                "name": "uveal melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9482,
                    "pubMedId": 28463630,
                    "title": "Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28463630"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11459,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Varlilumab resulted in stable disease in three patients with melanoma for 3.8, 7.3, and 11.5 months, respectively (PMID: 28463630).",
            "molecularProfile": {
                "id": 28056,
                "profileName": "CD27 positive"
            },
            "therapy": {
                "id": 2525,
                "therapyName": "Varlilumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9482,
                    "pubMedId": 28463630,
                    "title": "Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28463630"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11461,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Varlilumab resulted in stable disease for 5.7 months in a patient with colorectal adenocarcinoma (PMID: 28463630).",
            "molecularProfile": {
                "id": 28056,
                "profileName": "CD27 positive"
            },
            "therapy": {
                "id": 2525,
                "therapyName": "Varlilumab",
                "synonyms": null
            },
            "indication": {
                "id": 50861,
                "name": "colorectal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9482,
                    "pubMedId": 28463630,
                    "title": "Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28463630"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11458,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Varlilumab resulted in safety and tolerability, and led to stable disease in eight patients with an advanced solid tumor for greater than three months (PMID: 28463630).",
            "molecularProfile": {
                "id": 28056,
                "profileName": "CD27 positive"
            },
            "therapy": {
                "id": 2525,
                "therapyName": "Varlilumab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9482,
                    "pubMedId": 28463630,
                    "title": "Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28463630"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17391,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a mouse surrogate of CDX-527 enhanced T cell-mediated vaccine response in CD27 transgenic mice, resulted in anti-tumor activity in a syngeneic lymphoma model (AACR Annual Meeting 2019, Abstract 2392).",
            "molecularProfile": {
                "id": 28056,
                "profileName": "CD27 positive"
            },
            "therapy": {
                "id": 8483,
                "therapyName": "CDX-527",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15412,
                    "pubMedId": null,
                    "title": "CDX-527: A novel bispecific immune-modulating antibody targeting CD27 and PD-L1",
                    "url": "https://www.abstractsonline.com/pp8/#!/6812/presentation/2483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28056,
            "profileName": "CD27 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}